Skip to main content
UniHealth

Doctor search

Calin Arimie, MD

Gastroenterology · West Hills

NPI 1831277847

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
Not verified
Not the same as out of network.
Offices
2
Since medical school
36 years
Graduated 1990

Offices

2 locations · Genesis Healthcare Partners PC · 232 clinicians in this group

Looking this up.

Hospitals listed: Northridge Hospital Medical Center · UCLA West Valley Medical Center. That is not proof they admit you there this week.

Plan participation

Not verified

We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Arimie’s office to ask if they take your plan before you enroll.

California Medical Board record

Licence A63334 · Current

Licensed to practise in California · since 1997 · expires 2027-06-30 · Institute of Medicine and Pharmacy in Bucharest.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Surgery centers they own

  • Specialty Surgical Center of Encino LLC dba Specialty Surgical Center of EncinoAmbulatory Surgery Center · Encino, CA1% owner since 2024 · accredited by AAAHC
    Accreditation Renewed3 inspections, 2 with deficiencies · last 2025-04-10
  • Surgicare of West Hills, Inc.Ambulatory Surgery Center · West Hills, CA.7 owner since 2009 · accredited by AAAHC
    Accreditation Renewed4 inspections · last 2022-10-26

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Northridge Hospital Medical CenterNorthridge, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 3 of 5 · 66% would definitely recommend it
    Overall rating: 4 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.11, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.147, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.173, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
  • UCLA West Valley Medical CenterWest Hills, CAAcute Care Hospital · Proprietary · Has an emergency departmentPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 1 of 5 · 53% would definitely recommend it
    Overall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.454, Oct 2024 – Sep 2025
See every measure and the patient survey for Northridge Hospital Medical Center

Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 3 better, 4 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Northridge Hospital Medical Center
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.11BetterOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.147BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.173BetterOct 2024 – Sep 2025
MRSA BacteremiaInfections0BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.13 (0.13 to 2.13) · 1,012 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.78 (0.44 to 1.11)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths143.43 (96.43 to 190.42) · 88 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.2 · 40 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths8.2 · 92 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10.4 · 216 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths8 · 457 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.4 · 384 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.4 · 315 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3.7 · 3,091 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.25 (0.05 to 0.44) · 6,014 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.22 (0.02 to 0.41) · 6,139 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths2.59 (0.47 to 4.71) · 1,225 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.57 (0 to 3.24) · 299 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.81 (0.28 to 3.34) · 1,193 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths7.26 (0 to 15.07) · 333 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths6.14 (2.11 to 10.16) · 302 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.65 (0.17 to 3.14) · 163 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.14 (0 to 0.76) · 5,578 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4.2 · 139 casesNoneApr 2023 – Mar 2025
SSI - Colon SurgeryInfections1.041No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits14.1 · 368 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.6 · 674 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits27.2 · 214 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits26.2 · 563 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits23.8 · 438 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits17 · 484 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits4.9 (3.1 to 7.4) · 44 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits9.9 (6.8 to 13.8) · 44 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5 · 166 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits14.9 · 57 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits18.8 · 141 casesNoneJul 2023 – Jun 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.7 to 1.4) · 165 casesNo differentJan 2024 – Dec 2024

What patients said (621 patients answered, 15% of those asked)

Patient survey stars by topic at Northridge Hospital Medical Center
Cleanliness3
Nurse communication2
Doctor communication2
Communication about medicines3
Discharge information3
Overall hospital rating3
Quietness2
Recommend hospital3
Share of patients giving the best answer at Northridge Hospital Medical Center
Room was "always" clean69%
Nurses "always" communicated well74%
Doctors "always" communicated well72%
Staff "always" explained60%
Yes, staff "did" give patients this information86%
Yes, staff "did" give patients information about help after discharge84%
Doctors "always" explained things so they could understand66%
Doctors "always" listened carefully71%
Doctors "always" treated them with courtesy and respect78%
Patients who gave a rating of "9" or "10" (high)67%
Staff "always" explained new medications73%
Nurses "always" explained things so they could understand68%
Nurses "always" listened carefully73%
Nurses "always" treated them with courtesy and respect81%
"Always" quiet at night39%
"YES", patients would definitely recommend the hospital66%
Staff "always" explained possible side effects46%
Yes, staff "did" give patients information about possible symptoms88%
See every measure and the patient survey for UCLA West Valley Medical Center

Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 0 better, 7 the same, 0 worse of 7 measures. Readmissions: 0 better, 5 the same, 3 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at UCLA West Valley Medical Center
Clostridium Difficile (C.Diff)Infections0.454BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.87 (0 to 1.86) · 925 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.07 (0.74 to 1.41)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths126.11 (75.24 to 176.99) · 66 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.4 · 29 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.5 · 78 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths11 · 179 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths7.9 · 310 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths12.3 · 499 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.8 · 187 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3.4 · 2,150 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.15 (0 to 0.36) · 5,783 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.29 (0.09 to 0.48) · 5,787 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.94 (1.81 to 6.06) · 1,083 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.54 (0 to 3.21) · 337 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.83 (0.29 to 3.36) · 1,048 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths14.62 (6.73 to 22.51) · 354 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.07 (1.14 to 9) · 319 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.66 (0.18 to 3.15) · 221 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.46 (0 to 1.09) · 4,689 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 127 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.457No differentOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections1.124No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections1.781No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.838No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits14.2 · 201 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.8 · 400 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits5.5 · 173 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits8.2 · 369 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits51.5 · 534 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits17.5 · 569 casesNoneJul 2023 – Jun 2025
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 140 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits12.8 · 33 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20.3 · 105 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (9.3 to 17.4) · 30 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.7 to 1.5) · 136 casesNo differentJan 2024 – Dec 2024

What patients said (519 patients answered, 17% of those asked)

Patient survey stars by topic at UCLA West Valley Medical Center
Cleanliness2
Nurse communication1
Doctor communication1
Communication about medicines1
Discharge information2
Overall hospital rating1
Quietness1
Recommend hospital1
Share of patients giving the best answer at UCLA West Valley Medical Center
Room was "always" clean62%
Nurses "always" communicated well69%
Doctors "always" communicated well67%
Staff "always" explained49%
Yes, staff "did" give patients this information80%
Yes, staff "did" give patients information about help after discharge78%
Doctors "always" explained things so they could understand64%
Doctors "always" listened carefully64%
Doctors "always" treated them with courtesy and respect73%
Patients who gave a rating of "9" or "10" (high)52%
Staff "always" explained new medications64%
Nurses "always" explained things so they could understand67%
Nurses "always" listened carefully66%
Nurses "always" treated them with courtesy and respect74%
"Always" quiet at night39%
"YES", patients would definitely recommend the hospital53%
Staff "always" explained possible side effects35%
Yes, staff "did" give patients information about possible symptoms81%

Original Medicare doctor bills

$144,651

Medicare paid this office $144,651 for 444 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes208$22,406$102
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes132$20,571$62
Return visit (30+ min)102$15,024$97
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes103$9,054$39
Biopsy of large bowel using a flexible endoscope52$7,585$143
See all 18 services
Every Original Medicare service billed
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes208$22,406$102
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes132$20,571$62
Return visit (30+ min)102$15,024$97
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes103$9,054$39
Biopsy of large bowel using a flexible endoscope52$7,585$143
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope102$7,469$71
Insertion of stomach tube using a flexible endoscope39$6,343$163
Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month14$6,059$41
New patient visit (45+ min)46$5,718$124
Initial hospital care with moderate level of medical decision making at least 75 minutes37$5,344$141
Removal of polyps or growths of large bowel using an endoscope with mechanical snare22$4,585$199
Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month14$4,411$52
Short return visit (20+ min)43$3,495$71
New patient visit (30+ min)42$3,217$77
Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope19$2,898$132
Diagnostic exam of large bowel using a flexible endoscope24$2,785$111
Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope27$1,976$73
Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito15$70$5

Procedures Medicare counted

Procedure volume Medicare published
Colonoscopy117More than 83% of doctors who do this
Upper gastrointestinal (GI) endoscopy for acid reflux230More than 92% of doctors who do this

Procedures year by year

Procedures billed to Original Medicare by year
Procedure201920202021202220232024
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope10779608485105
Biopsy of large bowel using a flexible endoscope514730664953
Insertion of stomach tube using a flexible endoscope–2127203139
Removal of polyps or growths of large bowel using an endoscope with mechanical snare171413191123
Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope11–15201627
Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope–1711151522

Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.

Who their Medicare patients are

444 Original Medicare patients in 2024. Average age 75 · Under 65 8% · 85 and older 19% · Women 57% · Also on Medicaid 48% · Health risk score 2.27. Above the middle of the specialty; the typical gastroenterology clinician is at 1.42.

Conditions among them: High blood pressure 75% · Coronary heart disease 55% · Diabetes 50% · Heart failure 37% · Chronic kidney disease 37% · Depression 37% · Atrial fibrillation 30% · COPD 25% · Dementia 23% · Cancer 22% · Stroke 17%.

The office billed $940,655, Medicare allowed $189,606 and paid $144,651; for 1,783 services of 54 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20244441,783752.27$940,655$144,651
20233691,411742.24$727,747$122,938
20223561,364762.20$570,882$131,839
20213121,141762.13$354,343$110,184
20203001,260742.37$389,115$118,223
20193381,220752.15$285,589$111,856
20183571,310752.04$317,853$120,504
20173811,515752.35$314,447$123,987
20163171,081752.02$230,884$88,645
20153721,389742.17$322,755$129,967
20143041,066742.23$268,298$102,916
20133141,006752.28$325,637$99,573

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 16 services

Original Medicare services billed in 2023
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes130$29,313$66
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes161$19,676$106
Return visit (30+ min)117$15,974$99
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope85$6,521$77
Biopsy of large bowel using a flexible endoscope49$6,279$128
New patient visit (45+ min)50$5,479$110
Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month12$5,123$41
Insertion of stomach tube using a flexible endoscope31$4,852$157
Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month12$4,078$53
Colorectal cancer screening; colonoscopy on individual at high risk14$2,588$185
Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope14$2,332$155
Removal of polyps or growths of large bowel using an endoscope with mechanical snare11$2,155$196
Short return visit (20+ min)26$2,114$78
Diagnostic exam of large bowel using a flexible endoscope12$1,764$147
Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope16$1,433$90
Initial hospital care with moderate level of medical decision making at least 75 minutes11$1,383$126

2022: 11 services

Original Medicare services billed in 2022
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes160$29,649$59
Return visit (30+ min)124$20,779$101
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes159$19,115$112
Biopsy of large bowel using a flexible endoscope66$8,855$134
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope83$7,063$84
Initial hospital care with moderate level of medical decision making at least 75 minutes36$5,984$162
New patient visit (45+ min)46$5,672$123
Removal of polyps or growths of large bowel using an endoscope with mechanical snare19$4,126$217
Insertion of stomach tube using a flexible endoscope20$3,319$166
Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope13$2,385$159
Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope20$2,000$100

2021: 12 services

Original Medicare services billed in 2021
Return visit (30+ min)132$25,397$103
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes126$24,931$60
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes92$11,171$114
Initial hospital care with moderate level of medical decision making at least 75 minutes53$8,791$163
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope58$5,525$92
Insertion of stomach tube using a flexible endoscope27$4,668$173
New patient visit (45+ min)34$4,441$131
Biopsy of large bowel using a flexible endoscope30$3,587$120
Removal of polyps or growths of large bowel using an endoscope with mechanical snare13$2,863$220
Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope11$1,599$145
Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope15$1,441$96
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes14$984$33

2020: 13 services

Original Medicare services billed in 2020
Return visit (30+ min)149$23,700$91
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes85$16,964$62
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes87$12,011$117
Initial hospital care with moderate level of medical decision making at least 75 minutes60$11,427$176
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes86$7,734$34
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope74$6,244$79
Biopsy of large bowel using a flexible endoscope47$5,924$126
New patient visit (45+ min)28$3,796$136
Insertion of stomach tube using a flexible endoscope21$3,749$179
Removal of polyps or growths of large bowel using an endoscope with mechanical snare14$2,892$207
Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope14$2,877$169
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes13$2,016$92
Diagnostic exam of large bowel using a flexible endoscope12$1,894$158

2019: 13 services

Original Medicare services billed in 2019
Return visit (30+ min)145$21,665$87
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes111$12,990$33
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes100$12,521$114
Initial hospital care with moderate level of medical decision making at least 75 minutes61$10,702$173
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope101$9,849$92
Biopsy of large bowel using a flexible endoscope51$6,594$129
Insertion of stent into pancreatic or bile duct using a flexible endoscope15$6,114$408
New patient visit (45+ min)46$6,072$132
Removal of polyps or growths of large bowel using an endoscope with mechanical snare17$3,809$224
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes23$3,725$62
Diagnostic exam of large bowel using a flexible endoscope11$1,789$163
Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope11$1,137$103
Removal of stone or debris from bile or pancreatic duct using a flexible endoscope15$866$54

2018: 18 services

Original Medicare services billed in 2018
Return visit (30+ min)156$22,317$84
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes113$14,485$114
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes120$13,899$33
Biopsy of large bowel using a flexible endoscope57$9,037$159
Initial hospital care with moderate level of medical decision making at least 75 minutes51$8,876$171
Insertion of stent into pancreatic or bile duct using a flexible endoscope16$6,499$406
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope74$6,017$79
New patient visit (45+ min)46$5,743$125
Removal of stent from pancreatic or bile duct using a flexible endoscope11$3,635$330
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes30$3,530$62
Insertion of stomach tube using a flexible endoscope18$3,493$175
Colorectal cancer screening; colonoscopy on individual at high risk16$3,241$203
Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk15$3,042$203
Removal of polyps or growths of large bowel using an endoscope with mechanical snare13$2,740$211
Diagnostic exam of large bowel using a flexible endoscope16$2,474$146
Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope12$2,014$168
Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope17$1,380$81
Removal of stone or debris from bile or pancreatic duct using a flexible endoscope17$1,121$49

2017: 14 services

Original Medicare services billed in 2017
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes187$23,955$114
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes174$22,980$33
Return visit (30+ min)130$18,833$88
Biopsy of large bowel using a flexible endoscope61$8,962$147
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope87$8,289$90
Insertion of stent into pancreatic or bile duct using a flexible endoscope15$6,525$408
New patient visit (45+ min)43$5,717$133
Removal of polyps or growths of large bowel using an endoscope with mechanical snare19$3,900$205
Insertion of stomach tube using a flexible endoscope20$3,334$167
Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk12$2,443$204
Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope13$2,218$171
Diagnostic exam of large bowel using a flexible endoscope13$2,117$163
Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope16$1,574$98
Removal of stone or debris from bile or pancreatic duct using a flexible endoscope16$1,420$84

2016: 11 services

Original Medicare services billed in 2016
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes136$16,022$110
Return visit (30+ min)122$15,619$82
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes116$13,957$33
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope71$7,225$99
Biopsy of large bowel using a flexible endoscope38$5,332$140
Removal of polyps or growths of large bowel using an endoscope with mechanical snare19$3,816$201
New patient visit (45+ min)31$3,806$123
Insertion of stomach tube using a flexible endoscope16$3,013$177
Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope13$2,320$178
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes16$1,257$60
Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope11$997$91

2015: 17 services

Original Medicare services billed in 2015
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes168$22,076$115
Return visit (30+ min)128$20,935$90
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes138$17,403$33
Biopsy of large bowel using a flexible endoscope46$9,948$212
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope88$9,408$99
New patient visit (45+ min)46$6,164$134
Removal of polyps or growths of large bowel using an endoscope with mechanical snare23$5,729$249
Insertion of stent into pancreatic or bile duct using a flexible endoscope13$5,467$421
Diagnostic exam of large bowel using a flexible endoscope24$4,258$177
Control of bleeding of upper large bowel using a flexible endoscope12$3,954$282
Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope15$2,511$167
Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk11$2,463$224
Insertion of stomach tube using a flexible endoscope13$2,382$183
Removal of stone or debris from bile or pancreatic duct using a flexible endoscope14$1,556$86
Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope17$1,499$83
Short return visit (20+ min)15$1,109$58
New patient visit (30+ min)11$1,033$94

2014: 17 services

Original Medicare services billed in 2014
Return visit (30+ min)113$18,539$86
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes116$14,070$112
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes90$9,546$32
New patient visit (45+ min)45$5,788$129
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope56$5,664$96
Removal of polyps or growths of large bowel using an endoscope with mechanical snare18$4,734$249
Biopsy of large bowel using a flexible endoscope23$4,524$188
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes28$3,633$60
Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope19$3,486$174
Initial hospital care with moderate level of medical decision making at least 75 minutes17$2,756$162
Insertion of stomach tube using a flexible endoscope14$2,546$182
Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk11$2,520$229
Diagnostic exam of large bowel using a flexible endoscope14$2,410$172
Removal of stone or debris from bile or pancreatic duct using a flexible endoscope12$2,270$162
Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope19$1,977$94
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes11$1,100$85
Short return visit (20+ min)12$640$53

2013: 17 services

Original Medicare services billed in 2013
Return visit (30+ min)97$13,592$83
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes117$12,813$108
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes102$9,598$32
Removal of stone or debris from bile or pancreatic duct using a flexible endoscope14$6,400$427
Biopsy of large bowel using a flexible endoscope31$6,119$197
New patient visit (45+ min)40$5,376$134
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope46$4,707$100
Control of bleeding of upper large bowel using a flexible endoscope17$4,673$275
Removal of polyps or growths of large bowel using an endoscope with mechanical snare15$3,836$256
Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope15$3,637$227
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes35$3,460$59
Insertion of stomach tube using a flexible endoscope14$2,927$209
Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope23$2,445$106
Initial hospital care with moderate level of medical decision making at least 75 minutes14$2,250$161
Incision of pancreatic outlet using a flexible endoscope14$1,226$88
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes11$900$82
Short return visit (20+ min)12$808$62

Medicaid work

$2,773 in 2024

Medicaid paid $2,773 for 97 billed services this clinician did in 2024, up to 16 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES60$2,333
SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES37$440
Medicaid work by year
202497216$2,773
202341113$998
2022113316$2,904
2021158215$3,697
202079318$1,736
201963217$1,955
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES41$998

2022

Largest Medicaid services in 2022
1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES29$1,909
SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES44$560
Return visit (30+ min)40$434

2021

Largest Medicaid services in 2021
SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES100$3,697
Return visit (30+ min)58$0

2020

Largest Medicaid services in 2020
SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES48$1,640
Return visit (30+ min)13$96
New patient visit (45+ min)18$0

2019

Largest Medicaid services in 2019
1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES25$1,310
SBSQ HOSPITAL IP/OBS CARE SF/LOW MDM 25 MINUTES38$645

Drugs they prescribed that Part D paid

$176,968

Pharmacies billed $176,968 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 891) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.

730 generic and 161 brand-name prescriptions · $176,968 in drug cost · 34 antibiotic prescriptions to 17 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Linzess111$114,534$1,032
Omeprazole-Sodium Bicarbonate17$16,396$964
Movantik21$8,506$405
Sod Sulf-Potass Sulf-Mag Sulf142$8,460$60
Mesalamine28$8,166$292
See all 15 drugs
Every Part D drug this clinician prescribed
Linzess111$114,534$1,032
Omeprazole-Sodium Bicarbonate17$16,396$964
Movantik21$8,506$405
Sod Sulf-Potass Sulf-Mag Sulf142$8,460$60
Mesalamine28$8,166$292
Lansoprazole50$2,561$51
Omeprazole174$1,761$10
Esomeprazole Magnesium51$1,297$25
Pantoprazole41$588$14
Sucralfate28$585$21
Sulfasalazine17$500$29
Famotidine34$201$6
Ondansetron Odt14$170$12
Prednisone13$53$4
Metronidazole12$44$4

Year by year

Part D prescribing by year
20248913040% (0)18%$176,968
20238222960% (0)None$235,325
2022780290None37%$187,732
20217242360% (0)34%$234,495
2020921231None31%$267,737
2019912246None31%$222,736
20188802280% (0)41%$343,114
2017799232None43%$186,563
2016865239None41%$298,710
20157902212% (15)None$291,996
2014654198None37%$54,019
20136621844% (24)None$63,316

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 13 drugs

Part D drugs prescribed in 2023
Linzess85$107,772$1,268
Omeprazole-Sodium Bicarbonate21$57,344$2,731
Sod Sulf-Potass Sulf-Mag Sulf142$11,148$79
Mesalamine14$9,460$676
Dexlansoprazole Dr15$3,800$253
Omeprazole129$2,565$20
Lansoprazole35$2,514$72
Suprep13$1,506$116
Pantoprazole71$1,263$18
Esomeprazole Magnesium39$1,128$29
Sucralfate24$542$23
Famotidine38$432$11
Gavilyte-G26$417$16

2022: 13 drugs

Part D drugs prescribed in 2022
Linzess51$63,878$1,253
Suprep145$16,257$112
Mesalamine15$8,529$569
Budesonide Ec14$6,835$488
Esomeprazole Magnesium39$6,034$155
Lansoprazole32$2,300$72
Sod Sulf-Potass Sulf-Mag Sulf25$2,085$83
Omeprazole135$2,061$15
Sucralfate34$1,416$42
Pantoprazole74$1,139$15
Gavilyte-G23$293$13
Famotidine17$200$12
Ondansetron25$131$5

2021: 11 drugs

Part D drugs prescribed in 2021
Linzess84$84,987$1,012
Suprep91$9,882$109
Mesalamine14$9,797$700
Budesonide Ec11$9,227$839
Dexilant15$6,206$414
Esomeprazole Magnesium27$6,074$225
Lansoprazole37$5,764$156
Omeprazole155$2,329$15
Sucralfate34$1,205$35
Pantoprazole50$750$15
Famotidine35$696$20

2020: 18 drugs

Part D drugs prescribed in 2020
Linzess93$82,607$888
Pentasa11$16,115$1,465
Omeprazole-Sodium Bicarbonate24$15,320$638
Dexilant27$11,895$441
Amitiza17$11,302$665
Zenpep11$10,339$940
Suprep74$7,667$104
Esomeprazole Magnesium64$6,836$107
Lansoprazole29$6,582$227
Sucralfate34$3,302$97
Mercaptopurine12$2,962$247
Omeprazole213$2,773$13
Pantoprazole44$624$14
Megestrol Acetate12$584$49
Famotidine28$365$13
Prednisone22$221$10
Metronidazole15$163$11
Levofloxacin16$101$6

2019: 18 drugs

Part D drugs prescribed in 2019
Linzess82$65,912$804
Dexilant26$12,669$487
Budesonide Ec17$11,260$662
Amitiza18$9,895$550
Suprep83$8,198$99
Lansoprazole25$7,760$310
Esomeprazole Magnesium72$7,652$106
Omeprazole204$2,760$14
Balsalazide Disodium13$2,179$168
Mercaptopurine15$1,671$111
Sucralfate30$829$28
Pantoprazole35$382$11
Prednisone17$267$16
Famotidine19$255$13
Gavilyte-G17$206$12
Metronidazole15$167$11
Ranitidine20$123$6
Levofloxacin11$110$10

2018: 18 drugs

Part D drugs prescribed in 2018
Linzess128$75,130$587
Ocaliva23$73,078$3,177
Dexilant25$10,311$412
Amitiza12$7,362$614
Suprep70$6,468$92
Lansoprazole19$6,227$328
Budesonide Ec12$4,761$397
Esomeprazole Magnesium33$4,480$136
Nexium18$4,403$245
Omeprazole182$2,196$12
Moviprep17$1,725$101
Mercaptopurine15$1,721$115
Sucralfate22$669$30
Polyethylene Glycol 335015$532$35
Ranitidine30$364$12
Pantoprazole43$277$6
Prednisone14$139$10
Famotidine11$78$7

2017: 16 drugs

Part D drugs prescribed in 2017
Linzess86$36,183$421
Amitiza37$11,734$317
Dexilant27$10,236$379
Suprep102$9,001$88
Nexium35$8,958$256
Esomeprazole Magnesium17$3,372$198
Mercaptopurine20$1,970$98
Omeprazole135$1,929$14
Sucralfate28$911$33
Lansoprazole24$720$30
Polyethylene Glycol 335012$387$32
Ondansetron14$275$20
Diphenoxylate-Atropine11$192$17
Metronidazole15$159$11
Pantoprazole24$132$5
Levofloxacin15$119$8

2016: 15 drugs

Part D drugs prescribed in 2016
Linzess66$24,533$372
Amitiza46$17,968$391
Nexium40$10,415$260
Suprep110$9,123$83
Dexilant20$6,745$337
Prevacid11$4,082$371
Omeprazole213$2,617$12
Sucralfate47$1,441$31
Lansoprazole42$1,147$27
Metoprolol13$297$23
Pantoprazole33$276$8
Polyethylene Glycol 335013$245$19
Metronidazole12$163$14
Prednisone11$91$8
Levofloxacin13$79$6

2015: 16 drugs

Part D drugs prescribed in 2015
Linzess46$14,838$323
Nexium33$8,643$262
Suprep106$8,604$81
Amitiza32$8,496$266
Lansoprazole49$2,006$41
Omeprazole164$1,802$11
Rabeprazole16$990$62
Sucralfate24$789$33
Ondansetron12$297$25
Pantoprazole23$260$11
Spironolactone16$214$13
Generlac13$207$16
Metronidazole13$196$15
Levofloxacin15$176$12
Famotidine11$57$5
Hydrochlorothiazide12$48$4

2014: 15 drugs

Part D drugs prescribed in 2014
Nexium57$14,220$249
Linzess21$6,123$292
Suprep74$5,804$78
Aciphex11$3,973$361
Dexilant19$3,507$185
Omeprazole173$2,351$14
Rabeprazole14$1,219$87
Lansoprazole26$893$34
Sucralfate16$581$36
Pantoprazole30$527$18
Generlac13$287$22
Metronidazole19$255$13
Levofloxacin20$218$11
Lorazepam11$190$17
Famotidine11$136$12

2013: 15 drugs

Part D drugs prescribed in 2013
Aciphex25$9,051$362
Dexilant46$8,552$186
Nexium27$6,260$232
Amitiza14$5,260$376
Suprep65$4,730$73
Omeprazole168$3,192$19
Lansoprazole13$1,099$85
Pantoprazole44$1,049$24
Sucralfate16$588$37
Generlac11$271$25
Metronidazole15$254$17
Famotidine14$217$15
Levofloxacin14$158$11
Prednisone11$115$10
Tramadol22$109$5

Money from drug and device companies

$1,327 in 2025

Industry payments by year
2025839None$1,327
2024734None$1,107
2023530None$369
2022641None$844
2021325None$272
202012None$46
2019667None$627

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
ArdelyxIbsrela$458
12 payments
  • Meals for Ibsrela · 2025-12-10 · $34
  • Meals for Ibsrela · 2025-11-03 · $34
  • Meals for Ibsrela · 2025-10-15 · $7
  • Meals for Ibsrela · 2025-09-11 · $34
  • Meals for Ibsrela · 2025-07-22 · $33
  • Meals for Ibsrela · 2025-07-03 · $34
  • Meals for Ibsrela · 2025-06-05 · $32
  • Meals for Ibsrela · 2025-05-12 · $35
  • Meals for Ibsrela · 2025-04-07 · $33
  • Meals for Ibsrela · 2025-03-20 · $35
  • Meals for Ibsrela · 2025-02-20 · $30
  • Meals for Ibsrela · 2025-01-30 · $118
Madrigal PharmaceuticalsRezdiffra$247
4 payments
  • Meals for Rezdiffra · 2025-10-16 · $41
  • Meals for Rezdiffra · 2025-03-13 · $49
  • Meals for Rezdiffra · 2025-01-29 · $119
  • Meals for Rezdiffra · 2025-01-28 · $37
AbbvieCreon$190
14 payments
  • Meals for Creon · 2025-11-26 · $9
  • Meals for Creon · 2025-11-12 · $23
  • Meals for Linzess · 2025-11-04 · $10
  • Meals for Linzess · 2025-10-30 · $25
  • Meals for Creon · 2025-10-17 · $9
  • Meals for Creon · 2025-10-07 · $19
  • Meals for Linzess · 2025-09-09 · $4
  • Meals for Linzess · 2025-09-09 · $1
  • Meals for Creon · 2025-08-08 · $9
  • Meals for Creon · 2025-07-16 · $8
  • Meals for Creon · 2025-07-08 · $20
  • Meals for Linzess · 2025-04-16 · $21
  • Meals for Creon · 2025-03-25 · $4
  • Meals for Linzess · 2025-02-18 · $26
Janssen BiotechTremfya$181
4 payments
  • Meals for Tremfya · 2025-09-17 · $10
  • Meals for Tremfya · 2025-08-28 · $10
  • Meals for Tremfya · 2025-06-03 · $12
  • Meals for Tremfya · 2025-05-21 · $148
Phathom PharmaceuticalsVoquezna$150
1 payment
  • Meals for Voquezna · 2025-02-04 · $150
Salix Pharmaceuticals a division of Bausch Health USXifaxan$48
2 payments
  • Meals for Xifaxan · 2025-06-30 · $23
  • Meals for Xifaxan · 2025-04-21 · $25
See all 39 published payments
Every published payment
ArdelyxMeals · 2025-12-10Ibsrela$34
AbbvieMeals · 2025-11-26Creon$9
AbbvieMeals · 2025-11-12Creon$23
AbbvieMeals · 2025-11-04Linzess$10
ArdelyxMeals · 2025-11-03Ibsrela$34
AbbvieMeals · 2025-10-30Linzess$25
Novo NordiskMeals · 2025-10-23Wegovy$32
AbbvieMeals · 2025-10-17Creon$9
Madrigal PharmaceuticalsMeals · 2025-10-16Rezdiffra$41
ArdelyxMeals · 2025-10-15Ibsrela$7
AbbvieMeals · 2025-10-07Creon$19
Janssen BiotechMeals · 2025-09-17Tremfya$10
ArdelyxMeals · 2025-09-11Ibsrela$34
AbbvieMeals · 2025-09-09Linzess$4
AbbvieMeals · 2025-09-09Linzess$1
Janssen BiotechMeals · 2025-08-28Tremfya$10
AbbvieMeals · 2025-08-08Creon$9
ArdelyxMeals · 2025-07-22Ibsrela$33
AbbvieMeals · 2025-07-16Creon$8
AbbvieMeals · 2025-07-08Creon$20
ArdelyxMeals · 2025-07-03Ibsrela$34
Salix Pharmaceuticals a division of Bausch Health USMeals · 2025-06-30Xifaxan$23
ArdelyxMeals · 2025-06-05Ibsrela$32
Janssen BiotechMeals · 2025-06-03Tremfya$12
Janssen BiotechMeals · 2025-05-21Tremfya$148
ArdelyxMeals · 2025-05-12Ibsrela$35
Salix Pharmaceuticals a division of Bausch Health USMeals · 2025-04-21Xifaxan$25
AbbvieMeals · 2025-04-16Linzess$21
ArdelyxMeals · 2025-04-07Ibsrela$33
AbbvieMeals · 2025-03-25Creon$4
ArdelyxMeals · 2025-03-20Ibsrela$35
Madrigal PharmaceuticalsMeals · 2025-03-13Rezdiffra$49
ArdelyxMeals · 2025-02-20Ibsrela$30
AbbvieMeals · 2025-02-18Linzess$26
Phathom PharmaceuticalsMeals · 2025-02-04Voquezna$150
ArdelyxMeals · 2025-01-30Ibsrela$118
Madrigal PharmaceuticalsMeals · 2025-01-29Rezdiffra$119
Madrigal PharmaceuticalsMeals · 2025-01-28Rezdiffra$37
Ironwood PharmaceuticalsMeals · 2025-01-16Linzess$22
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $1,107

Payments by company in 2024
Janssen BiotechTremfya$512
12 payments
  • Meals for Tremfya · 2024-11-21 · $13
  • Meals for Tremfya · 2024-10-29 · $21
  • Meals for Tremfya · 2024-10-24 · $142
  • Meals for Tremfya · 2024-09-25 · $18
  • Meals for Tremfya · 2024-09-25 · $119
  • Meals for Tremfya · 2024-09-25 · $12
  • Meals for Stelara · 2024-08-21 · $16
  • Meals for Stelara · 2024-07-26 · $16
  • Meals for Stelara · 2024-06-20 · $13
  • Meals for Tremfya · 2024-05-08 · $125
  • Meals for Tremfya · 2024-04-02 · $9
  • Meals for Tremfya · 2024-02-06 · $9
Ironwood PharmaceuticalsLinzess$198
13 payments
  • Meals for Linzess · 2024-12-05 · $28
  • Meals for Linzess · 2024-10-29 · $6
  • Meals for Linzess · 2024-10-15 · $9
  • Meals for Linzess · 2024-08-22 · $8
  • Meals for Linzess · 2024-07-30 · $24
  • Meals for Linzess · 2024-07-16 · $10
  • Meals for Linzess · 2024-05-21 · $19
  • Meals for Linzess · 2024-05-07 · $10
  • Meals for Linzess · 2024-04-24 · $19
  • Meals for Linzess · 2024-04-03 · $20
  • Meals for Linzess · 2024-03-12 · $11
  • Meals for Linzess · 2024-02-14 · $21
  • Meals for Linzess · 2024-01-03 · $12
Phathom PharmaceuticalsVoquezna$125
1 payment
  • Meals for Voquezna · 2024-07-25 · $125
AbbvieCreon$99
4 payments
  • Meals for Creon · 2024-10-31 · $25
  • Meals for Creon · 2024-08-28 · $22
  • Meals for Linzess · 2024-06-19 · $24
  • Meals for Skyrizi · 2024-02-22 · $28
Madrigal PharmaceuticalsRezdiffra$61
1 payment
  • Meals for Rezdiffra · 2024-10-26 · $61
ArdelyxIbsrela$59
2 payments
  • Meals for Ibsrela · 2024-12-02 · $30
  • Meals for Ibsrela · 2024-10-22 · $29
Boston ScientificAdvanix Biliary$53
1 payment
  • Meals for Advanix Biliary · 2024-10-01 · $53

2023: $369

Payments by company in 2023
Ironwood PharmaceuticalsLinzess$159
13 payments
  • Meals for Linzess · 2023-12-07 · $14
  • Meals for Linzess · 2023-11-21 · $26
  • Meals for Linzess · 2023-11-08 · $14
  • Meals for Linzess · 2023-10-25 · $10
  • Meals for Linzess · 2023-06-15 · $10
  • Meals for Linzess · 2023-06-01 · $10
  • Meals for Linzess · 2023-05-16 · $12
  • Meals for Linzess · 2023-04-25 · $11
  • Meals for Linzess · 2023-03-22 · $8
  • Meals for Linzess · 2023-03-08 · $12
  • Meals for Linzess · 2023-02-14 · $11
  • Meals for Linzess · 2023-01-25 · $12
  • Meals for Linzess · 2023-01-11 · $8
AbbVieViberzi$153
14 payments
  • Meals for Linzess · 2023-11-17 · $11
  • Meals for Viberzi · 2023-10-24 · $11
  • Meals for Viberzi · 2023-10-10 · $8
  • Meals for Viberzi · 2023-10-05 · $11
  • Meals for Viberzi · 2023-08-25 · $15
  • Meals for Skyrizi · 2023-08-16 · $22
  • Meals for Viberzi · 2023-07-28 · $13
  • Meals for Skyrizi · 2023-06-28 · $16
  • Meals for Viberzi · 2023-06-21 · $9
  • Meals for Skyrizi · 2023-04-06 · $13
  • Meals for Viberzi · 2023-02-28 · $12
  • Meals for Viberzi · 2023-02-09 · $8
  • Meals for Linzess · 2023-02-09 · $1
  • Meals for Linzess · 2023-02-09 · $2
Janssen BiotechStelara$29
1 payment
  • Meals for Stelara · 2023-09-08 · $29
Salix Pharmaceuticals a division of Bausch Health USTrulance$15
1 payment
  • Meals for Trulance · 2023-01-11 · $15
GenzymeDupixent$13
1 payment
  • Meals for Dupixent · 2023-02-01 · $13

2022: $844

Payments by company in 2022
AbbvieRinvoq$271
16 payments
  • Meals for Creon · 2022-11-29 · $11
  • Meals for Viberzi · 2022-11-01 · $7
  • Meals for Rinvoq · 2022-08-26 · $19
  • Meals for Rinvoq · 2022-08-18 · $22
  • Meals for Skyrizi · 2022-08-11 · $12
  • Meals for Rinvoq · 2022-08-09 · $13
  • Meals for Rinvoq · 2022-08-02 · $16
  • Meals for Rinvoq · 2022-07-22 · $26
  • Meals for Rinvoq · 2022-07-15 · $30
  • Meals for Rinvoq · 2022-07-14 · $30
  • Meals for Viberzi · 2022-05-04 · $9
  • Meals for Rinvoq · 2022-04-19 · $26
  • Meals for Linzess · 2022-04-15 · $12
  • Meals for Rinvoq · 2022-04-13 · $28
  • Meals for Creon · 2022-02-03 · $5
  • Meals for Creon · 2022-01-11 · $5
Ironwood PharmaceuticalsLinzess$175
19 payments
  • Meals for Linzess · 2022-12-20 · $12
  • Meals for Linzess · 2022-11-30 · $10
  • Meals for Linzess · 2022-11-16 · $7
  • Meals for Linzess · 2022-10-27 · $7
  • Meals for Linzess · 2022-10-11 · $8
  • Meals for Linzess · 2022-09-21 · $8
  • Meals for Linzess · 2022-09-02 · $8
  • Meals for Linzess · 2022-08-16 · $11
  • Meals for Linzess · 2022-08-05 · $5
  • Meals for Linzess · 2022-06-28 · $9
  • Meals for Linzess · 2022-06-07 · $10
  • Meals for Linzess · 2022-05-24 · $10
  • Meals for Linzess · 2022-04-27 · $8
  • Meals for Linzess · 2022-04-14 · $13
  • Meals for Linzess · 2022-03-22 · $10
  • Meals for Linzess · 2022-03-08 · $10
  • Meals for Linzess · 2022-02-24 · $11
  • Meals for Linzess · 2022-02-09 · $6
  • Meals for Linzess · 2022-01-25 · $11
E.R. Squibb & Sons L.L.C.Zeposia$150
2 payments
  • Meals for Zeposia · 2022-04-19 · $141
  • Education for Zeposia · 2022-02-02 · $9
Regeneron Healthcare SolutionsDupixent$138
2 payments
  • Meals for Dupixent · 2022-12-13 · $8
  • Meals for Dupixent · 2022-11-22 · $130
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)Lifevest$98
1 payment
  • Meals for Lifevest · 2022-08-01 · $98
GenzymeDupixent$13
1 payment
  • Meals for Dupixent · 2022-09-20 · $13

2021: $272

Payments by company in 2021
Ironwood PharmaceuticalsLinzess$134
14 payments
  • Meals for Linzess · 2021-12-09 · $7
  • Meals for Linzess · 2021-11-30 · $10
  • Meals for Linzess · 2021-11-16 · $11
  • Meals for Linzess · 2021-10-21 · $12
  • Meals for Linzess · 2021-10-07 · $10
  • Meals for Linzess · 2021-09-23 · $8
  • Meals for Linzess · 2021-09-02 · $11
  • Meals for Linzess · 2021-08-12 · $11
  • Meals for Linzess · 2021-07-01 · $11
  • Meals for Linzess · 2021-04-21 · $8
  • Meals for Linzess · 2021-03-23 · $7
  • Meals for Linzess · 2021-03-09 · $9
  • Meals for Linzess · 2021-02-18 · $10
  • Meals for Linzess · 2021-02-02 · $11
AbbVieHumira$122
10 payments
  • Meals for Viberzi · 2021-10-20 · $9
  • Meals for Linzess · 2021-09-30 · $7
  • Meals for Humira · 2021-08-17 · $20
  • Meals for Linzess · 2021-08-07 · $6
  • Meals for Humira · 2021-07-15 · $20
  • Meals for Humira · 2021-06-02 · $20
  • Meals for Humira · 2021-04-15 · $24
  • Meals for Viberzi · 2021-03-31 · $7
  • Meals for Linzess · 2021-02-03 · $9
  • Meals for Linzess · 2021-02-03 · $1
Salix Pharmaceuticals a division of Bausch Health USXifaxan$16
1 payment
  • Meals for Xifaxan · 2021-08-18 · $16

2020: $46

Payments by company in 2020
AbbVieHumira$46
2 payments
  • Meals for Humira · 2020-12-11 · $24
  • Meals for Humira · 2020-07-08 · $22

2019: $627

Payments by company in 2019
AllerganLinzess$342
53 payments
  • Meals for Zenpep · 2019-12-19 · $6
  • Meals for Zenpep · 2019-12-05 · $7
  • Meals for Linzess · 2019-12-03 · $9
  • Meals for Zenpep · 2019-11-21 · $5
  • Meals for Linzess · 2019-11-12 · $6
  • Meals for Zenpep · 2019-11-07 · $6
  • Meals for Zenpep · 2019-10-31 · $7
  • Meals for Zenpep · 2019-10-24 · $4
  • Meals for Linzess · 2019-10-22 · $7
  • Meals for Bystolic · 2019-10-18 · $12
  • Meals for Zenpep · 2019-10-17 · $6
  • Meals for Zenpep · 2019-10-10 · $7
  • Meals for Zenpep · 2019-10-03 · $7
  • Meals for Linzess · 2019-10-01 · $7
  • Meals for Linzess · 2019-09-26 · $7
  • Meals for Linzess · 2019-09-19 · $6
  • Meals for Linzess · 2019-09-10 · $8
  • Meals for Zenpep · 2019-09-03 · $6
  • Meals for Zenpep · 2019-08-29 · $7
  • Meals for Zenpep · 2019-08-22 · $5
  • Meals for Linzess · 2019-08-20 · $8
  • Meals for Zenpep · 2019-08-15 · $6
  • Meals for Zenpep · 2019-08-08 · $7
  • Meals for Zenpep · 2019-08-01 · $6
  • Meals for Linzess · 2019-07-18 · $6
  • Meals for Linzess · 2019-07-16 · $7
  • Meals for Linzess · 2019-06-27 · $5
  • Meals for Zenpep · 2019-06-20 · $6
  • Meals for Linzess · 2019-06-18 · $10
  • Meals for Zenpep · 2019-06-13 · $5
  • Meals for Zenpep · 2019-06-06 · $5
  • Meals for Viberzi · 2019-05-30 · $5
  • Meals for Linzess · 2019-05-28 · $7
  • Meals for Viberzi · 2019-05-16 · $6
  • Meals for Viberzi · 2019-05-09 · $6
  • Meals for Linzess · 2019-05-07 · $8
  • Meals for Viberzi · 2019-05-02 · $6
  • Meals for Viberzi · 2019-04-25 · $6
  • Meals for Viberzi · 2019-04-18 · $3
  • Meals for Linzess · 2019-04-17 · $6
  • Meals for Viberzi · 2019-04-11 · $7
  • Meals for Viberzi · 2019-04-04 · $5
  • Meals for Viberzi · 2019-03-07 · $6
  • Meals for Linzess · 2019-03-05 · $7
  • Meals for Viberzi · 2019-02-28 · $5
  • Meals for Viberzi · 2019-02-14 · $7
  • Meals for Linzess · 2019-02-12 · $7
  • Meals for Viberzi · 2019-02-07 · $7
  • Meals for Viberzi · 2019-01-31 · $7
  • Meals for Viberzi · 2019-01-24 · $6
  • Meals for Linzess · 2019-01-22 · $6
  • Meals for Viberzi · 2019-01-17 · $5
  • Meals for Viberzi · 2019-01-10 · $5
Salix Pharmaceuticals a division of Bausch Health USPlenvu$155
9 payments
  • Meals for Xifaxan · 2019-09-06 · $8
  • Meals for Trulance · 2019-07-25 · $3
  • Meals for Trulance · 2019-07-25 · $7
  • Meals for Trulance · 2019-06-17 · $7
  • Meals for Trulance · 2019-05-22 · $8
  • Meals for Trulance · 2019-04-29 · $8
  • Meals for Trulance · 2019-04-24 · $9
  • Meals for Xifaxan · 2019-02-06 · $7
  • Meals for Plenvu · 2019-01-15 · $100
Braintree LaboratoriesSuprep Bowel Prep$53
1 payment
  • Gift for Suprep Bowel Prep · 2019-08-23 · $53
AbbVieHumira$34
2 payments
  • Meals for Humira · 2019-11-27 · $14
  • Meals for Humira · 2019-02-19 · $20
Richard Wolf Medical InstrumentsNone$25
1 payment
  • Meals · 2019-02-05 · $25
Apollo Endosurgery USOverstitch$17
1 payment
  • Meals for Overstitch · 2019-01-29 · $17

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study To Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Crohn'S Disease · 2022Their institution$80,000
Boehringer Ingelheim International GmbH · Proof of Clinical Principal in Crohn'S Disease · 2024Their institution$62,887
Eli Lilly and Company · A Phase 3, Multicenter, Open Label, Long Term Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Crohns Disease · 2024Their institution$59,816
Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study To Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Crohn'S Disease · 2020Their institution$57,626
Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study To Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Crohn'S Disease · 2021Their institution$42,197
Eli Lilly and Company · A Phase 3, Multicenter, Open Label, Long Term Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Crohns Disease · 2025Their institution$33,920
Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 1) · 2019Their institution$28,556
Eli Lilly and Company · A Phase 3 Multicenter Randomized Double-Blind Placebo- and Active- Controlled Treat-Through Study To Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Crohn'S Disease · 2023Their institution$24,192
Eli Lilly and Company · A Phase 3, Multicenter, Open-Label Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis Lucent 3 · 2021Their institution$22,618
Eli Lilly and Company · A Phase 3, Multicenter, Open Label, Long Term Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Crohns Disease · 2022Their institution$19,326
Eli Lilly and Company · A Phase 3 Multicenter Open-Label Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis Lucent 3 · 2023Their institution$19,254
Eli Lilly and Company · A Phase 3, Multicenter, Open-Label Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis Lucent 3 · 2022Their institution$18,741
Eli Lilly and Company · A Phase 3 Multicenter Open Label Long Term Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Crohns Disease · 2023Their institution$17,979
Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 2) · 2020Their institution$16,155
Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 1) · 2020Their institution$15,706
Eli Lilly and Company · A Phase 3, Multicenter, Open Label, Long Term Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Crohns Disease · 2021Their institution$15,289
ABBVIE INC. · A Study To Assess the Change in Disease Activity in Adult Participants With Moderate To Severe Ulcerative Colitis Treated With Risankizumab Compared To Vedolizumab (Revamp) · 2025Their institution$11,690
Boehringer Ingelheim Pharma GmbH & Co.KG · Proof of Clinical Principal in Crohn?S Disease · 2023Their institution$9,710
Eli Lilly and Company · A Multicenter, Phase 3b, Open-Label, Single-Arm Study To Investigate Bowel Urgency and Its Relationship With Other Outcome Measures in Adults With Moderately To Severely Active Ulcerative Colitis Treated With Mirikizumab · 2024Their institution$9,484
Boehringer Ingelheim International GmbH · Proof of Clinical Principal in Crohn?S Disease · 2023Their institution$8,642
Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 2) · 2022Their institution$7,066
Boehringer Ingelheim International GmbH · Proof of Clinical Principal in Crohn?S Disease · 2022Their institution$7,050
Eli Lilly and Company · A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo Or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately To Severely Active Ulcerative Colitis and Obesity Or Overweight · 2025Their institution$5,070
Boehringer Ingelheim Pharma GmbH & Co.KG · Proof of Clinical Principal in Crohn?S Disease · 2022Their institution$4,690
Boehringer Ingelheim International GmbH · A Phase Iia, Randomised, Double-Blind, Placebo-Controlled Trial To Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Bi 706321 Orally Administered for 12 Weeks in Patients With Crohn`S Disease (Cd) Receiving Ustekinumab Induction Tre · 2025Their institution$4,589
GlaxoSmithKline, LLC. · A Multicentre Randomized, Double-Blind, Placebo-Controlled Phase 2 Stu · 2021Their institution$4,400
Eli Lilly and Company · A Multicenter, Phase 3b, Open-Label, Single-Arm Study To Investigate Bowel Urgency and Its Relationship With Other Outcome Measures in Adults With Moderately To Severely Active Ulcerative Colitis Treated With Mirikizumab · 2025Their institution$4,000
Takeda Pharmaceuticals U.S.A., Inc. · P3 Ac Vdz To Ada in UC N=658, 2 Arms, US-Eu · 2019Their institution$3,723
Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 1) · 2022Their institution$3,673
Eli Lilly and Company · A Phase 3, Multicenter, Open-Label Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis Lucent 3 · 2024Their institution$3,524
Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study To Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Crohn'S Disease · 2020This clinician$3,328
Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study To Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Crohn'S Disease · 2025Their institution$2,500
Boehringer Ingelheim Pharma GmbH & Co.KG · Proof of Clinical Principal in Crohn'S Disease · 2024Their institution$1,765
Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 1) · 2019This clinician$1,592
Eli Lilly and Company · A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo Or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately To Severely Active Crohns Disease and Obesity Or Overweight · 2025Their institution$1,095
Eli Lilly and Company · A Multicenter Phase 3b Open-Label Single-Arm Study To Investigate Bowel Urgency and Its Relationship With Other Outcome Measures in Adults With Moderately To Severely Active Ulcerative Colitis Treated With Mirikizumab · 2023This clinician$860
Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 2) · 2019This clinician$488
Eli Lilly and Company · A Phase 3, Multicenter, Open-Label Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis Lucent 3 · 2020Their institution$436
Roche Products Limited · Crohn S Disease Program Cohort 1 Induction Cohort II Maintenance · 2022Their institution$340
Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 2) · 2020This clinician$28
Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 1) · 2020This clinician$26
Boehringer Ingelheim Pharma GmbH & Co.KG · Proof of Clinical Principal in Crohn???S Disease · 2025Their institution$9

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
84.0 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1831277847
Licence
CA A63334California A63334: Current · expires 2027-06-30
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207RG0100X (207RG0100X)
Mailing address
7320 Woodlake Ave, Ste 260, West Hills, CA, 91307
NPI first listed
2006-11-01
NPI last updated
2017-01-17

This is when the NPI record was last certified, not a medical board exam.